【1】2022年，多款FDA批准的新药针对的是历史上难以成药的靶点，主要侧重共价抑制和别构抑制等机制

【2】一些蛋白降解疗法针对难以成药靶点，已迈入临床试验。未来此类技术有望成为攻克“难以成药”靶点的生力军

【3】针对诸如p53、Myc、WEE1等不可成药靶点，多个科研团队设计出了可靠的针对性策略，并有望拓展到其他不可成药或难以成药的靶点。

【4】在解决“难以成药”的靶点上，产业投融资事件较为活跃，共有47起早期投融资事件（涉及43家新锐），融资约28.5亿美元。扫描文中二维码或点击文末“阅读原文/Read more”，即可访问下载页面，获取这些新锐的详细列表。

FDA新药：共价或别构抑制

蛋白降解疗法，未来的生力军

多项科学突破引人关注，未来可期

投资赋能技术，别开蹊径解决不可成药

结语

[1] U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis. Retrieved September 9, 2022, from https://investors.bms.com/iframes/press-releases/press-release-details/2022/U.S.-Food-and-Drug-Administration-Approves-Sotyktu-deucravacitinib-Oral-Treatment-for-Adults-with-Moderate-to-Severe-Plaque-Psoriasis/default.aspx

[2] Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation. Retrieved December 12, 2022, from https://www.prnewswire.com/news-releases/mirati-therapeutics-announces-us-fda-accelerated-approval-of-krazati-adagrasib-as-a-targeted-treatment-option-for-patients-with-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc-with-a-krasg12c-mutation-301700902.html

[3] FDA and EMA Accept Regulatory Submission for Pfizer’s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata. Retrieved September 9, 2022 from https://www.pfizer.com/news/press-release/press-release-detail/fda-and-ema-accept-regulatory-submission-pfizers

[4] Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress. Retrieved October 17, 2022 from https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-and-biogen-present-further-analyses-phase-3

[5] Kymera Therapeutics Doses First Patients in Phase 1 Oncology Trials of STAT3 and IRAKIMiD Degraders KT-333 and KT-413. Retrieved June 15, 2022 from https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-doses-first-patients-phase-1-oncology-trials

[6] Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC). Retrieved November 22, 2022 from https://ir.arvinas.com/news-releases/news-release-details/arvinas-announces-arv-471-achieves-clinical-benefit-rate-38

[7] Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development. Retrieved May 26, 2022, from https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-announces-positive-dose-finding-data-chronic

[8] Guiley and Shokat, (2022). A small molecule reacts with the p53 somatic mutant Y220C to rescue wild-type thermal stability. Cancer Discovery, https://doi.org/10.1158/2159-8290.CD-22-0381

[9] Nested Therapeutics Launches With $125 Million Financing. Retrieved October 7, 2022, from https://www.prnewswire.com/news-releases/nested-therapeutics-launches-with-125-million-financing-301642107.html

[10] Samarasinghe et al., (2022). OligoTRAFTACs: A generalizable method for transcription factor degradation. RSC Chemical Biology, DOI: 10.1039/d2cb00138a

[11] Henning et al., (2022). Deubiquitinase-targeting chimeras for targeted protein stabilization. Nature Chemical Biology, https://doi.org/10.1038/s41589-022-00971-2

[12] Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease. Retrieved July 28, 2022 from https://www.vicinitastx.com/news.html

[13] ODYSSEY THERAPEUTICS ANNOUNCES OVERSUBSCRIBED $168 MILLION SERIES B FINANCING. Retrieved October 13, 2022, from https://odysseytx.com/news/

[14] OMass Therapeutics Raises $100 Million in Series B Financing to Progress Drug Pipeline in Immunology and Rare Diseases. Retrieved December 26, 2022，from https://www.omass.com/2022/04/28/omass-therapeutics-raises-100-million-in-series-b-financing-to-progress-drug-pipeline-in-immunology-and-rare-diseases/

[15] Septerna Launches With $100 Million Series A Financing to Expand the Frontier of GPCR-Targeted Medicines Using the Native Complex™ Platform. Retrieved January 27, 2022, from https://septerna.com/press-releases/septerna-launches-with-100-million-series-a-financing-to-expand-the-frontier-of-gpcr-targeted-medicines-using-the-native-complex-platform/

[16] TRIANA Biomedicines Launches With $110M to Unlock the Full Potential of Molecular Glues. Retrieved April 7, 2022, from https://www.businesswire.com/news/home/20220406005125/en/%C2%A0TRIANA-Biomedicines-Launches-With-110M-to-Unlock-the-Full-Potential-of-Molecular-Glues

[17] Bonum Therapeutics Announces a $93M Series A Financing to Advance a Novel and Validated Class of Conditionally Active Therapies. Retrieved November 15, 2022 from https://www.businesswire.com/news/home/20221115005420/en/Bonum-Therapeutics-Announces-a-93M-Series-A-Financing-to-Advance-a-Novel-and-Validated-Class-of-Conditionally-Active-Therapies

[18] GluBio Completes Series A+ Financing of $22 Million to Advance the Development of Novel TPD Drugs. Retrieved December 26, 2022, from https://www.prnewswire.com/news-releases/glubio-completes-series-a-financing-of-22-million-to-advance-the-development-of-novel-tpd-drugs-301596564.html

分享，点赞，在看，聚焦全球生物医药健康创新